3SBio: Balancing Growth Prospects With Financial Challenges – A Hold Rating by Sean Wu, CFA

TipRanksAug 23 07:03 ET

Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target Is HK$6.50

MT NewswiresAug 22 03:52 ET

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.42 From HK$6.16, Keeps at Buy

MT NewswiresAug 14 04:32 ET

HUTCHMED (China) Analyst Ratings

BenzingaAug 1 13:36 ET

Hold Rating on HUTCHMED Amid Promising U.S. Launch and Pending EU Reimbursement Clarity

TipRanksJul 31 17:53 ET

Nomura Adjusts Hansoh Pharmaceutical's Price Target to HK$17.23 From HK$15.03, Keeps at Neutral

MT NewswiresJul 23 04:34 ET

Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.83 From HK$10.07, Keeps at Buy

MT NewswiresJul 23 04:34 ET

Nomura Adjusts Innovent Biologics' Price Target to HK$55.87 From HK$55.31, Keeps at Buy

MT NewswiresJul 16 03:26 ET

Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 107.91 Yuan From 118.48 Yuan, Keeps at Buy

MT NewswiresJul 11 04:08 ET

Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$76.45 From HK$83.94, Keeps at Buy

MT NewswiresJul 11 04:08 ET

Goldman Sachs Keeps Their Hold Rating on HUTCHMED (HCM)

TipRanksJul 9 15:38 ET

Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$10.07 From HK$9.41, Keeps at Buy

MT NewswiresMay 28 04:04 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)

TipRanksMay 15 15:45 ET

Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy

MT NewswiresApr 26 04:47 ET

Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)

TipRanksApr 5 05:50 ET

Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$6.16 From HK$6.63, Keeps at Buy

MT NewswiresMar 15 06:24 ET

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.41 From HK$8.98, Keeps at Buy

MT NewswiresMar 14 08:47 ET

Nomura Adjusts Asymchem Laboratories Tianjin's Price Target to HK$90.12 From HK$134.59, Keeps at Buy

MT NewswiresMar 4 05:37 ET

HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential

TipRanksFeb 28 16:55 ET

Nomura Adjusts Innovent Biologics' Price Target to HK$55.31 From HK$54.51, Keeps at Buy

MT NewswiresFeb 26 04:12 ET